37812 Federal Register / Vol. 83, No. 149 / Thursday, August 2, 2018 / Notices 

the adequate replacement test will likely 

proceed pursuant to the less rigorous 

alternative options test. The 

Commission estimates that the total 

annual burden of the entire collection, 

as revised, is reduced from 1,923 hours 

to 1,086 hours. 

Federal Communications Commission. 

Marlene Dortch, 

Secretary. Office of the Secretary. 

[FR Doc. 2018–16513 Filed 8–1–18; 8:45 am] 

BILLING CODE 6712–01–P 

FEDERAL ELECTION COMMISSION 

Sunshine Act Meeting 

TIME AND DATE: Tuesday, August 7, 2018 

at 10:00 a.m. 

PLACE: 1050 First Street NE, 

Washington, DC 

STATUS: This meeting will be closed to 

the public. 

MATTERS TO BE CONSIDERED: Compliance 

matters pursuant to 52 U.S.C. 30109. 

Matters relating to internal personnel 

decisions, or internal rules and 

practices. 

Information the premature disclosure 

of which would be likely to have a 

considerable adverse effect on the 

implementation of a proposed 

Commission action. 

Matters concerning participation in 

civil actions or proceedings or 

arbitration. 

* * * * * 

CONTACT PERSON FOR MORE INFORMATION: 

Judith Ingram, Press Officer, Telephone: 

(202) 694–1220. 

Dayna C. Brown, 

Secretary and Clerk of the Commission. 

[FR Doc. 2018–16700 Filed 7–31–18; 4:15 pm] 

BILLING CODE 6715–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[Docket No. ATSDR–2015–0001] 

Availability of Set 29 Draft 

Toxicological Profiles 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of availability; request 

for comment. 

SUMMARY: The Agency for Toxic 

Substances and Disease Registry 

(ATSDR), within the Department of 

Health and Human Services (HHS) 

announces the availability of Set 29 

Draft Toxicological Profiles for review 

and comment. All toxicological profiles 

issued as ‘‘Drafts for Public Comment’’ 

represent ATSDR’s best efforts to 

provide important toxicological 

information on priority hazardous 

substances. ATSDR is seeking public 

comments and additional information or 

reports on studies about the health 

effects of Tribufos, 

Bromodichloromethane, 

Bromomethane, and 2-Hexanone for 

review and potential inclusion in the 

profiles. Although ATSDR considers key 

studies for these substances during the 

profile development process, this 

document solicits any relevant, 

additional information. ATSDR will 

evaluate the quality and relevance of 

such data or studies for possible 

inclusion into the profile. 

ATSDR also seeks comments on the 

organization and format of the 

Toxicological Profile for 

Bromodichloromethane. In an effort to 

improve the usability of the profiles, 

ATSDR recently made content and 

organizational changes based on user 

feedback, as well as data identifying the 

most used profile content. Changes 

include: Removing redundant content; 

adding summary figures and tables to 

Chapters 1, 2, 5, and 6 that did not exist 

in previous Toxicological Profiles; and 

reformatting the Levels of Significant 

Exposure (LSE) tables in Chapter 2. 

ATSDR has only applied the changes to 

the Draft Toxicological Profile for 

Bromodichloromethane, but intends to 

use the new format for future profiles. 

Specifically, ATSDR would like to 

know: 

(1) Does the chapter organization 

make it easier for you to find the 

information you need? For example, are 

you satisfied with the organization of 

the health effects chapter by organ 

system rather than exposure route? 

(2) Are the new tables and figures 

clear and useful? Do they make the 

Toxicological Profile easier to read? 

(3) If you have previously used any 

Toxicological Profile(s) for your work, 

which parts or content are the most 

useful to you, and what do you use it 

for? 

(4) Does the profile contain all of the 

information you need? If no, please 

elaborate on what additional 

information would be helpful. 

(5) Is there information you would 

like to see in the profile that is not 

currently included? If yes, please 

elaborate on the additional information 

you would like to see in the profile. 

ATSDR remains committed to 

providing a public comment period for 

these documents as a means to provide 

the best service to the public regarding 

public health. 

DATES: Comments must be submitted by 

October 31, 2018. 

ADDRESSES: You may submit comments, 

identified by docket number ATSDR– 

2015–0001, by either of the following 

methods: 

• Internet: Access the Federal 

eRulemaking Portal at 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of Toxicology and 

Human Health Sciences, Agency for 

Toxic Substances and Disease Registry, 

1600 Clifton Rd. NE, MS F–57, Atlanta, 

GA, 30329. Attn: Docket No. ATSDR– 

2015–0001. 

Instructions: All submissions must 

include the agency name and docket 

number for this notice. All relevant 

comments will be posted without 

change. This means that no confidential 

business information or other 

confidential information should be 

submitted in response to this notice. 

The public comments, responses, and 

other data submitted in response to the 

Federal Register notices are available by 

request from ATSDR. Contact CDC Info 

at 1–800–232–4636 or cdcinfo@cdc.gov 

to request this information. 

FOR FURTHER INFORMATION CONTACT: 

Susan Ingber, Agency for Toxic 

Substances and Disease Registry, 

Division of Toxicology and Human 

Health Sciences, 1600 Clifton Rd. NE, 

MS F–57, Atlanta, GA, 30329, Email: 

ATSDRToxProfileFRNs@cdc.gov; Phone: 

1–800–232–4636. 

SUPPLEMENTARY INFORMATION: The 

Superfund Amendments and 

Reauthorization Act of 1986 (SARA) [42 

U.S.C. 9601 et seq.] amended the 

Comprehensive Environmental 

Response, Compensation, and Liability 

Act of 1980 (CERCLA or Superfund) [42 

U.S.C. 9601 et seq.] by establishing 

certain requirements for ATSDR and the 

U.S. Environmental Protection Agency 

(EPA) regarding hazardous substances 

that are most commonly found at 

facilities on the CERCLA National 

Priorities List (NPL). Among these 

statutory requirements is a mandate for 

the Administrator of ATSDR to prepare 

toxicological profiles for each substance 

included on the priority list of 

hazardous substances [also called the 

Substance Priority List (SPL)]. This list 

identifies 275 hazardous substances that 

ATSDR and EPA have determined pose 

the most significant potential threat to 

human health. The SPL is available 

online at www.atsdr.cdc.gov/spl. 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 149 / Thursday, August 2, 2018 / Notices 37813 

In addition, CERCLA provides ATSDR 

with the authority to prepare 

toxicological profiles for substances not 

found on the SPL. CERCLA authorizes 

ATSDR to establish and maintain 

inventory of literature, research, and 

studies on the health effects of toxic 

substances (CERCLA Section 

104(i)(1)(B)); to respond to requests for 

health consultations (CERCLA Section 

104(i)(4)); and to support the sitespecific response actions conducted by 

the agency. 

Availability 

The Draft Toxicological Profiles are 

available online at http://

www.atsdr.cdc.gov/ToxProfiles and at 

www.regulations.gov, Docket No. 

ATSDR–2015–0001. 

Pamela I. Protzel Berman, 

Director, Office of Policy, Partnerships and 

Planning, Agency for Toxic Substances and 

Disease Registry. 

[FR Doc. 2018–16557 Filed 8–1–18; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Community Living 

Announce the Intent To Award an 

Administrative Supplement 

ACTION: Announcing the Intent to Award 

an Administrative Supplement for two 

(2) Help America Vote Act (HAVA) 

Training and Technical Assistance 

(T/TA) grantees, the National Disability 

Rights Network (NDRN) 90HAVA0001 

and the National Federation of the Blind 

(NFB) 90HAVA0002. 

SUMMARY: The Administration for 

Community Living (ACL) announces the 

intent to award an administrative 

supplement to the current Help America 

Vote Act (HAVA) Training and 

Technical Assistance (T/TA) grantees 

held by the National Disability Rights 

Network (NDRN) and the National 

Federation of the Blind (NFB). The 

purpose of the HAVA programs are 

designed to establish and improve 

participation in the election process for 

individuals with a full range of 

disabilities. In each eligible state and 

territory, seven percent of HAVA funds 

are set aside for the Protection and 

Advocacy Systems (P&As) to ensure that 

individuals with disabilities have the 

opportunity to participate in every step 

of the voting process. After receiving 

training and technical assistance, P&As 

may inform others on the availability of 

accessible voting equipment and its use. 

The administrative supplement for FY 

2018 will be in the amount of $122,721 

bringing the total award for FY 2018 to 

$462,590. 

Program Name: Help America Vote 

Act Training and Technical Assistance. 

Recipients: National Disability Rights 

Network (NDRN) and National 

Federation of the Blind (NFB). 

Period of Performance: The 

supplement award will be issued for the 

second year of the two-year project 

period of September 1, 2018, through 

August 30, 2019. 

Total Award Amount: NDRN 

$326,274 in FY 2018 NFB $136,316 in 

FY2018. 

Award Type: Administrative 

Supplement. 

Statutory Authority: This program is 

authorized under Title II, Subtitle D, 

Part 5 of HAVA 42 U.S.C. 15461–62, 

Section 102 of the Developmental 

Disabilities Assistance and Bill of Rights 

Act of 2000 (DD Act) (42 U.S.C. 15002). 

Basis for Award: The additional 

funding will not be used to begin new 

projects. The funding will be used to 

increase NDRN’s capacity building 

efforts to provide training and technical 

assistance to the Protection and 

Advocacy Systems in the electoral 

process and NFB will be able to attend 

voting related conferences, conduct 

voting outreach campaigns and translate 

materials into Spanish. 

FOR FURTHER INFORMATION CONTACT: For 

further information or comments 

regarding this program supplement, 

contact Melvenia Wright, U.S. 

Department of Health and Human 

Services, Administration for 

Community Living, Administration on 

Disabilities, Administration on 

Intellectual and Developmental 

Disabilities: telephone (202) 795–7472; 

email Melvenia.Wright@acl.hhs.gov. 

Dated: July 26, 2018. 

Lance Robertson, 

Administrator and Assistant Secretary for 

Aging. 

[FR Doc. 2018–16561 Filed 8–1–18; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0126] 

Revocation of Authorization of 

Emergency Use of an In Vitro 

Diagnostic Device for Detection of 

Ebola Virus 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

revocation of the Emergency Use 

Authorization (EUA) (the Authorization) 

issued to Zalgen Labs, LLC for the 

ReEBOV Antigen Rapid Test. FDA 

revoked this Authorization on May 18, 

2018, under the Federal Food, Drug, and 

Cosmetic Act (FD&C Act), as requested 

by Zalgen Labs, LLC by letter dated 

March 1, 2018. The revocation, which 

includes an explanation of the reasons 

for revocation, is reprinted in this 

document. 

DATES: The Authorization is revoked as 

of May 18, 2018. 

ADDRESSES: Submit written requests for 

single copies of the revocation to the 

Office of Counterterrorism and 

Emerging Threats, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 1, Rm. 4338, Silver Spring, 

MD 20993–0002. Send one selfaddressed adhesive label to assist that 

office in processing your request or 

include a Fax number to which the 

revocation may be sent. See the 

SUPPLEMENTARY INFORMATION section for 

electronic access to the revocation. 

FOR FURTHER INFORMATION CONTACT: 

Michael Mair, Office of 

Counterterrorism and Emerging Threats, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 1, Rm. 

4336, Silver Spring, MD 20993–0002, 

301–796–8510 (this is not a toll-free 

number). 

SUPPLEMENTARY INFORMATION: 

I. Background 

Section 564 of the FD&C Act (21 

U.S.C. 360bbb–3) as amended by the 

Project BioShield Act of 2004 (Pub. L. 

108–276) and the Pandemic and AllHazards Preparedness Reauthorization 

Act of 2013 (Pub. L. 113–5) allows FDA 

to strengthen the public health 

protections against biological, chemical, 

nuclear, and radiological agents. Among 

other things, section 564 of the FD&C 

Act allows FDA to authorize the use of 

an unapproved medical product or an 

unapproved use of an approved medical 

product in certain situations. On 

February 24, 2015, FDA issued an EUA 

to Corgenix, Inc. for the ReEBOV 

Antigen Rapid Test, subject to the terms 

of the Authorization. Notice of the 

issuance of the Authorization was 

published in the Federal Register on 

June 5, 2015 (80 FR 32140), as required 

by section 564(h)(1) of the FD&C Act. In 

response to requests from Zalgen Labs, 

LLC and Corgenix, Inc. to transfer 

ownership of the EUA for the ReEBOV 

Antigen Rapid Test from Corgenix, Inc. 

to Zalgen Labs, LLC, FDA amended and 

reissued the EUA to Zalgen Labs, LLC 


daltland on DSKBBV9HB2PROD with NOTICES